High quality RU58841 for hair growth CAS: 154992-24-2

RU-58841 RU58841 Quack Detail

Product Name:RU58841

Application:Specific androgen receptor antagonist

CAS:154992-24-2

Molar Mass:369.34 g/mol

Chemical Formula:C17H18F3N3O3

Synonyms:PSK-3841, HMR-3841

Storage Minimize open air exposure, store in a cool dry place

Reports FT-IR/HPLC

Terms The products we offer are intended for laboratory research use only.

Please familiarize yourself with our Term& Conditions prior to ordering.

RU58841 is an androgen receptor blocker. It binds to androgen receptors with great specificity and tenacity, but does not activate the receptor. Its presence on the receptor prevents androgens such as DHT from binding to and activating the receptor. It has been extensively studied as a topical agent to treat acne and androgenetic alopecia (1, 2, 3).

Androgenetic alopecia, or male-pattern balding, is caused by DHT binding to androgen receptors in the hair follicles. Over time, in susceptible individuals, the activation of the androgen receptors causes the hair follicles to stop producing normal hair and to undergo a process called miniaturization. In laboratory studies, RU58841 has been shown to be quite effective in competing against DHT for access to the androgen receptors.

RU58841 Description

RU-58841 is a new non-steroidal specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. The potent localized inhibition of sebaceous glands by RU 58841 demonstrates the excellent potential of this compound as a topical drug for the treatment of acne and other androgen-mediated disorders. Synonym: RU-58841; RU58841; RU 58841.

RU58841 is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of RU58841 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery.

the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of RU58841 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to RU58841 and the treatment of acne and prostate cancer, which are conditions also driven however, the most recent study published in relation to RU58841 was back in 2008.